Overall, the pharmaceutical industry is moving away from an approach where AI is task-driven, narrowly focused on a single, isolated problem. Instead, companies are embracing foundation models which, trained on very large and broad datasets, are versatile, and capable of tackling a range of complex challenges simultaneously.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Brendan Frey, founder and chief innovation officer of Deep Genomics, an AI-first TechBio organisation working on a genome biology foundation AI platform.

From Nobel Prizes connected to the company’s work in the field, to mining RNA biology data and Deep Genomics’ own foundation model for this – Frey explains why standard approaches are simply too slow and costly.

You can also listen to episode 199a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.